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Abstract Here we studied the role of phosphoinositide 3-kinase
(PI 3-kinase) and mitogen activated protein (MAP) kinase in
regulating bradykinin (BK) induced prostaglandin E2 (PGE2)
production in human pulmonary artery smooth muscle cells
(HPASMC). BK increased PGE2 in a three step process involv-
ing phospholipase A2 (PLA2), cyclooxygenase (COX) and PGE
synthase (PGES). BK stimulated PGE2 release in cultured
HPASMC was inhibited by the PI 3-kinase inhibitor
LY294002 and the p38 MAP kinase inhibitor SB202190. The
inhibitory mechanism used by LY294002 did not involve cyto-
solic PLA2 activation or COX-1, COX-2 and PGES protein
expression but rather a novel e¡ect on COX enzymatic activity.
SB202190 also inhibited COX activity.
6 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Key words: Bradykinin; Cyclooxygenase; Prostaglandin E2 ;
Phosphoinositide 3-kinase; Mitogen-activated protein kinase
1. Introduction
Bradykinin (BK) is a nonapeptide formed from the proteo-
lytic cleavage of high molecular weight kininogen by plasma
kallikrein and is an important in£ammatory mediator con-
cerned with the maintenance of normal cardiovascular func-
tion [1]. BK produces many of its e¡ects through the second-
ary generation of prostanoids. For example BK induces
increased prostaglandin E2 (PGE2) release in both human
and bovine cultured airway smooth muscle (ASM) cells and
human pulmonary artery smooth muscle cells (HPASMC) [2^
4]. PGE2 has important functional e¡ects including inhibiting
smooth muscle cell proliferation and inducing vasodilation
and may act as a negative feedback mechanism in the patho-
genesis of pulmonary hypertension [5,6].
Prostaglandins are produced from arachidonic acid (AA)
by the combined actions of phospholipase A2 (PLA2), cyclo-
oxygenase (COX) and speci¢c terminal prostaglandin syn-
thases. PLA2 mobilises AA from membrane phospholipids
and exists in several di¡erent forms that are categorised ac-
cording to molecular weight, calcium dependence and cellular
localisation [7,8]. The intracellular, cytosolic PLA2 (cPLA2)
isoforms are activated by increases in intracellular calcium
concentrations induced by in£ammatory mediators such as
BK [9]. AA is then converted to PGH2 by COX. There are
three isoforms of cyclooxygenase, COX-1, COX-2 and COX-
3. COX-1, which is constitutively expressed, is associated with
the immediate response and basal levels of prostanoid produc-
tion. COX-2 is induced in response to in£ammatory cytokines
and mediators and results in increased and sustained prosta-
noid release [10]. The recently characterised COX-3 is consti-
tutively expressed in speci¢c tissue with highest levels in the
brain and heart [11]. Enzymes downstream of COX isomer-
ases and synthases are responsible for the production of ter-
minal prostaglandins. PGH2 is converted to PGE2 by prosta-
glandin E synthase (PGES) of which there are two di¡erent
forms [12]. Cytosolic PGES (cPGES) is expressed constitu-
tively in many cell types and is associated with COX-1 derived
PGH2 [13]. Microsomal PGES (mPGES) is induced by in£am-
matory cytokines such as interleukin (IL)-1L and is associated
with COX-2 derived PGH2 [14].
Phosphoinositide 3-kinases (PI 3-K) are a family of kinases
that regulate a diverse array of cellular responses such as
di¡erentiation, proliferation, activation and survival by gen-
erating lipid second messengers [15]. Using the speci¢c PI 3-K
inhibitor LY294002 [16], mitogen stimulated proliferation in
human airway smooth cells was shown to be mediated by PI
3-Ks [17]. Mitogen activated protein (MAP) kinases are acti-
vated by in£ammatory mediators [18]. As hypoxic induction
of COX-2 in distal HPASMC is dependent on p38 MAP ki-
nase [19] we also studied the e¡ect of MAP kinase inhibitors.
The role of PI 3-K in regulating prostanoid synthesis in
HPASMC has not been studied. Here we investigate the
mechanisms involved in BK induced PGE2 release in
HPASMC focussing on the role of PI 3-K. We found that
BK induced PGE2 was mediated via cPLA2; COX and PGES.
We found that LY294002 inhibited PGE2 production due to a
novel e¡ect on COX enzymatic activity.
2. Materials and methods
2.1. Cell culture
Proximal HPASMC were purchased at passage 3 from Clonetics0
(BioWhittaker UK, Wokingham, Berkshire, UK). The PASMC were
cultured to passage 6 in smooth muscle cell growth medium-2
BulletKit0 (Clonetics0 BioWhittaker UK).
All experiments were set up in triplicate or quadruplicate using
passage 6 cells cultured in 6 or 24 well plates at 37‡C in a 5% CO2,
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humidi¢ed incubator (Leec, Colwick, Nottingham, UK). The con£u-
ent cells were growth arrested by serum withdrawal for 24 h. The
medium was replaced with fresh serum free medium containing the
cytokines or peptides under investigation. The cells were pre-incuba-
ted for 1 h with the inhibitors. At the end of the incubation time the
culture supernatants were harvested and the protein was extracted
from the cells.
2.2. Assessment of cell viability
One well of the 24 well plate in each condition was detached using
0.025% trypsin and 0.01% EDTA. The cell number and percentage
viability were assessed using a haemocytometer and 0.4% trypan blue
(Sigma, Poole, Dorset, UK).
2.3. PGE2 assay
PGE2 levels were assessed by radioimmunoassay (RIA) as described
previously [3,20]. The bound [3H]PGE2 (Amersham Pharmacia Bio-
tech, Little Chalfont, Bucks., UK) was measured using the Tri-Carb
2100TR liquid scintillation analyser (Packard Bioscience, Pangbourne,
Berkshire, UK). The PGE2 levels were calculated with Riasmart soft-
ware (Packard Bioscience). PGE2 was chosen because it is the main
prostaglandin produced by PASMC [6].
2.4. [3H]AA release
Con£uent PASMC were growth arrested by withdrawal of serum
for 24 h. The medium was then replaced with serum-free medium
containing 18.5 kBq/ml of [3H]AA (Amersham Pharmacia Biotech)
and the cells incubated for 16 h. The culture supernatant was removed
and the cells washed three times in sterile serum free medium. The
cells were then treated with or without 10 WM BK and 1 WM
LY294002 for 0.25, 0.5, 1, 2, 3 and 4 h. The antibiotic and calcium
ionophore calcimycin A23187 was used as a positive control. After the
incubation times the supernatants were removed and the released
[3H]AA was counted using Tri-Carb 2100TR liquid scintillation ana-
lyser and Emulsi¢er Safe liquid scintillation cocktail (Packard Bio-
science). The remaining cells were lysed with 0.1% Triton X-100 (Sig-
ma) and counted as above. The percentage [3H]AA release was
calculated as follows:
% ½3HAA release ¼
radioactivity in medium
radioactivity in medium þ radioactivity in cell lysateU100
2.5. Western blot analysis
Western blotting for COX-1 and COX-2 was performed as de-
scribed previously [4]. Western blotting for cPGES and mPGES was
performed in the same manner but used sheep anti-human polyclonal
primary antibodies (Cayman Chemical, Bingham, Nottinghamshire,
UK). The goat anti-sheep and anti-mouse horseradish peroxidase con-
jugated secondary antibody was purchased from BD Biosciences
(Cowley, Oxford, UK). Staining intensity of the bands was measured
using a densitometer (Syngene, Braintree, Essex, UK) together with
Genesnap and Genetools software (Syngene). The ¢gures depicting
Western blotting are representative of four blots.
2.6. Assay of COX activity using exogenous AA
Using con£uent growth arrested HPASMC, the medium was re-
placed with medium containing either 1 WM LY294002 or 0.2% di-
methyl sulphoxide (DMSO) as a vehicle control and incubated at
37‡C for 30 min. The cells were incubated for a further 30, 60, 90
or 120 min with or without 10 WM BK. At the end of the incubation
times the supernatants were removed and assayed for PGE2. The cells
were washed twice in sterile phosphate-bu¡ered saline and incubated
for a further 30 min with medium containing 1 WM AA. The super-
natants were removed and assayed for PGE2.
2.7. Materials
BK, LY294002 ([2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-
6
Fig. 1. A: Time course of PGE2 production in PASMC treated
with 10 WM BK for 0, 2, 4, 6, 8, 16 and 24 h and unstimulated
cells. The PGE2 released into the culture medium was measured by
RIA. Each point represents the meanQS.E.M. of quadruple deter-
minations from three independent experiments. ***P6 0.001 by
ANOVA. B: Western blotting showing time dependent COX-2 pro-
tein induction by BK. PASMC were incubated for 0, 2, 4, 6, 8, 16
and 24 h with 10 WM BK. COX-2 protein expression was maximal
at 4 h whereas COX-1 protein expression was constitutive. The ¢g-
ure is representative of four blots from independent experiments.
C: Concentration related inhibition of BK induced PGE2 release by
the PI 3-K inhibitor LY294002. Con£uent growth arrested
HPASMC were cultured with concentrations of LY294002 ranging
from 1 nM to 1 WM followed by 4 h incubation with 10 WM BK.
**P6 0.01, *P6 0.05 by ANOVA. Subsequent experiments used
1 WM LY294002. D: The increased BK mediated PGE2 production
(***P6 0.001 by ANOVA) is inhibited by 1 WM indomethacin and
1 WM NS398 (þþþP6 0.001 by ANOVA).
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one]) and DMSO were purchased from Sigma. The MEK inhibitor
PD98059 and potent MAP kinase inhibitor SB202190 were purchased
from Calbiochem (Merck Biosciences, Nottingham, UK).
2.8. Statistical analysis
The results of the PGE2 levels and [3H]AA release were expressed
as the mean of the triplicate or quadruplicate wells for each experi-
ment which were repeated at least three times. The results shown
represent the mean and S.E.M. Analysis of variance (ANOVA) was
used to determine signi¢cant di¡erences. A P value of 6 0.05, two
tailed, was considered to be signi¢cant.
3. Results
3.1. BK induced PGE2 production is inhibited by the PI 3-K
inhibitor LY294002
We have previously reported that BK induces COX-2 pro-
tein and stimulates PGE2 release in cultured HPASMC [2].
Here we found a signi¢cant increase in PGE2 levels in cells
treated with 10 WM BK at 2, 4, 8, 16 and 24 h compared with
unstimulated control cells (Fig. 1A). Western blotting showed
that BK induced COX-2 protein with bands detected at 2, 4,
8, 16 and 24 h, with the strongest bands at 4 and 8 h, while
the constitutively expressed COX-1 protein was constant at all
the time points (Fig. 1B). As the COX-2 protein band was
Fig. 2. A: BK stimulation for 30, 60 and 120 min induced a signi¢-
cant increase in [3H]AA release compared with unstimulated cells.
Each point represents the meanQS.E.M. of quadruple determina-
tions from three independent experiments. **P6 0.01, *P6 0.05 by
ANOVA. B: Incubation for 1 h with 10 WM BK induced an in-
crease in [3H]AA release which was not inhibited by 1 WM
LY294002. Each point represents the meanQS.E.M. of quadruple
determinations from three independent experiments. **P6 0.01 by
ANOVA.
Fig. 3. A: Western blotting showing COX-1, COX-2 and cPGES
expression in response to 4 h incubation with 10 WM BK and the
a¡ect of LY294002. The blot is representative of four separate ex-
periments. B,C: The relative protein expression measured by densi-
tometry of COX-2 and cPGES expression that has been normalised
to COX-1 protein, respectively, n=4.
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strong at 4 h we chose this time point for most subsequent
experiments.
Pre-incubation for 30 min with the speci¢c PI 3-K inhibitor
LY294002 before incubation with BK for 4 h resulted in a
dose dependent reduction in PGE2 release which was signi¢-
cant with 0.1 and 1 WM LY294002 (Fig. 1C). 0.2% DMSO
was used as a vehicle control. 1 WM LY294002 gave the most
signi¢cant reduction in PGE2 without a¡ecting cell viability.
This concentration was used in the subsequent experiments.
LY294002 had no e¡ect on basal PGE2 production in unstim-
ulated control cells suggesting that it was not acting on COX-
1.
3.2. LY294002 does not inhibit BK increased cPLA2 activity
Con£uent, growth arrested HPASMC were incubated with
10 WM BK for 0.5, 1, 2, 3, and 4 h. BK induced increased
[3H]AA release at 0.5, 1 and 2 h compared with unstimulated
control cells (Fig. 2A). However, there was no reduction in
BK mediated [3H]AA release after pre-incubation with 1 WM
LY294002 (Fig. 2B).
3.3. LY294002 does not inhibit COX-1, COX-2 or cPGES
protein expression
In order to determine if LY294002 a¡ected COX protein or
PGES expression, Western blotting was performed using spe-
ci¢c monoclonal antibodies to COX-1 or COX-2 and a rabbit
polyclonal antibody to cPGES. COX-1 and cPGES were con-
stitutively expressed. Maximal COX-2 expression was induced
by incubation for 4 h with BK. The mPGES protein was
induced by IL-1L but not BK in HPASMC but only after
48 h incubation (data not shown). There was no detectable
reduction in either COX-1, COX-2 or cPGES expression as a
result of pre-treatment with LY294002 (Fig. 3).
3.4. LY294002 inhibits COX activity
To determine whether the reduction in PGE2 by inhibition
of PI 3-K was due to a decrease in COX activity we measured
COX activity by adding exogenous AA and measuring PGE2
production. PASMC were cultured for 30 min with medium
containing either 0.2% DMSO or 1 WM LY294002 followed
by 30, 60, 90 or 120 min with or without 10 WM BK. The
supernatants were removed for PGE2 assay and replaced with
medium containing 1 WM AA for a further 30 min. This
medium was removed and assayed for PGE2. There was a
reduction in PGE2 release post AA in cells that had been
incubated with LY294002 prior to BK suggesting inhibition
of COX activity (Fig. 4).
3.5. SB202190 inhibits BK mediated PGE2 and COX activity
To investigate whether MAP kinase pathways were in-
volved in BK induced PGE2 production we performed experi-
ments with the potent p38 MAP kinase inhibitor SB202190
and the MEK inhibitor PD98059. SB202190 signi¢cantly re-
duced BK mediated PGE2 release (Fig. 5A) and COX activity
(Fig. 5B) whereas PD98059 had no e¡ect on COX activity
(data not shown).
4. Discussion
We found that BK induced PGE2 release in a three step
process involving mobilisation of AA from cPLA2, induction
Fig. 4. HPASMC were incubated for 30 min with either 1 WM
LY294002 or 0.2% DMSO vehicle control and then cultured for 30,
60, 90 or 120 min with 10 WM BK and the medium removed. Me-
dium containing 1 WM AA was added for a further 30 min. This
medium was assayed for PGE2. The post AA PGE2 levels re£ect
the degree of COX activity. ***P6 0.001, **P6 0.01, *P6 0.05 by
ANOVA.
Fig. 5. A: HPASMC were incubated for 30 min with either 1 WM
of the potent p38 MAP kinase inhibitor SB202190 or 0.2% DMSO
vehicle control and then cultured for 4 h with 10 WM BK and the
medium removed and assayed for PGE2. B: Medium containing 1
WM AA was added for a further 30 min. This medium was assayed
for PGE2. The post AA PGE2 levels re£ect the degree of COX ac-
tivity. **P6 0.01, *P6 0.05 by ANOVA.
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of COX-2 and action of cPGES. There was no increase in
mPGES, the inducible form of PGES. Cytosolic PGES is ex-
pressed constitutively whereas the microsomal PGES is induc-
ible in some cells by in£ammatory cytokines, such as IL-1L.
Western blotting showed that cPGES expression did not
change in the presence of LY294002. Culture of HPASMC
with IL-1L resulted in induction of mPGES at 48 and 72 h but
not at 4 h. BK did not induce mPGES at any time point (data
not shown).
The increased PGE2 release with BK was abrogated by the
presence of the speci¢c PI 3-K inhibitor LY294002 suggesting
that one or more mechanisms involved in PGE2 generation is
dependent on PI 3-K signalling. We designed a series of ex-
periments to explore the site in the pathway that was in-
volved. We initially studied the e¡ect of LY294002 on cPLA2,
the enzyme upstream of COX. We found no e¡ect of
LY294002 on cPLA2 activity measured as AA release. We
have previously shown that di¡erent COX enzymes partici-
pate in PGE2 release at di¡erent times after BK stimulation.
We found no e¡ect of LY294002 on COX-1 protein expres-
sion or basal COX-1 derived PGE2 levels. Similarly COX-2
protein expression did not change signi¢cantly in the presence
of LY294002 suggesting that it was not acting to prevent
COX-2 induction. However, when we measured COX activity
by adding exogenous AA to BK stimulated cells we found
that it was inhibited by LY294002. cPGES, the downstream
enzyme that converts PGH2 to PGE2, was unchanged.
These results contrast with studies in other biological sys-
tems. In colonic epithelial cells tumour necrosis factor-K in-
duced COX-2 and increased PGE2 production which was par-
adoxically enhanced by PI 3-K inhibition [21]. Both IL-1L
mediated COX-2 induction and PGE2 production in canine
tracheal smooth muscle cells was reduced by PI 3-K inhibi-
tion, suggesting partial involvement of PI 3-K activation in
COX-2 induction [22]. In contrast LY294002 inhibited stau-
rosporine induced PGE2 generation in rat peritoneal macro-
phages by inhibiting cPLA2 but did not a¡ect COX-2 induc-
tion [23]. Previous studies in HeLa cells have shown that BK
activates PI 3-K [24]. Our results with SB202190 suggest that
p38 MAP kinases also play a role in regulating COX-2 activ-
ity.
Collectively these studies suggest that PI 3-K can regulate
PGE2 production through di¡erent mechanisms in a cell and
species speci¢c manner. In HPASMC PI 3-K and p38 MAP
kinase inhibition results in a reduction in PGE2 release medi-
ated by inhibition of COX enzymatic activity.
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